Other languages Scinai Immunotherapeutics Ltd.

Equities

SCNI

US09073Q2049

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.4828 ^USD	+5.19%		+0.67%	-18.91%

Apr. 08	Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	MT
Apr. 08	Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	Apr. 08
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	Apr. 08
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales	Feb. 13
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds	Dec. 29
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31
Scinai Immunotherapeutics Launches $1.33 Million Registered Direct Offering	23-09-15
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	23-09-06
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Top Premarket Gainers	23-06-05
BiondVax Pharmaceuticals Ltd. Signs Exclusive License Agreement for Development and Commercialization of A Novel Anti-II-17 Antibody for Treatment of Autoimmune and Inflammatory Diseases Including Psoriasis	23-06-05
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
BiondVax Pharmaceuticals Ltd. Announces Resignation of George H. Lowell as Member of the Board	23-05-11
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17
Biondvax Pharmaceuticals Ltd. Announces Additional Results in Preclinical Proof-of-Concept Study of its Innovative Inhaled NanoAb COVID-19 Drug	23-01-23
BiondVax Says Its COVID-19 Treatment Candidate Lowered Presence of Coronavirus in Animal Study	23-01-06
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study	23-01-06
Top Midday Decliners	22-12-16
BiondVax Prices $8 Million Public Offering; Shares Decline	22-12-16
BiondVax Pharmaceuticals Regains Compliance with Nasdaq Listing Rules	22-12-12
BiondVax Pharmaceuticals Ltd. Appoints Dr. med. Matthias Dobbelstein as Member its Scientific Advisory Board	22-12-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Scinai Immunotherapeutics Ltd.

Equities

SCNI

US09073Q2049

Other languages

Filters